



Geneva, Switzerland  
15-18 APRIL 2015

EUROPEAN LUNG CANCER  
CONFERENCE

Save the date

## Preliminary Programme

Wednesday, 15 April 2015

<b>12:15-13:15</b> Room A	<i>Industry Satellite Symposium 1</i>	
<b>13:15-13:40</b>	<b>Welcome Reception</b>	
<b>13:45-14:00</b> Room B	<b>Opening and Welcome</b>	<b>Chairs: To be announced</b>
5'	Welcome to the Conference	Dominique Grunenwald, FR and Johan Vansteenkiste, BE
5'	Intro to ESMO (President)	Rolf A. Stahel, CH
5'	Intro to IASLC (President)	Tony S.K. Mok, CN
<b>14:00-14:30</b> Room B	<b>Keynote Lecture</b>	<b>Chairs: To be announced</b>
30'	The development of oncological platforms across Europe	Rolf A. Stahel, CH
<b>14:30-16:00</b> Room B	<b>Educational session</b> <b>Local control after treatment of early stage lung cancer</b>	<b>Chairs: To be announced</b>
20'	Stereotactic ablative RT after surgical treatment	Suresh Senan, NL
20'	Surgery after stereotactic ablative RT	Paul Van Schil, BE
20'	Surgery after radiofrequency ablation	Hendrik Dienemann, DE
20'	Surgery for metachronous lung tumours	David Jones , US
10'	Questions and Answers	
<b>14:30-16:00</b> Room A	<b>Educational session</b> <b>The evolving role of immunotherapy for lung cancer</b>	<b>Chairs: To be announced</b>
20'	Checkpoint inhibitors: State of the art	Solange Peters, CH
20'	Combination strategies	Martin Reck, DE
20'	Any room left for vaccines in lung cancer?	Johan Vansteenkiste, BE
20'	Clinical trial design and perspectives	David Carbone, US
15'	Questions and Answers	
<b>16:00-16:30</b>	<b>Coffee break</b>	

Wednesday, 15 April 2015, cont.

<b>16:30-18:00</b> <b>Room B</b>	<b>Educational session</b> <b>Mesothelioma: The rare disease that we need to know better</b>	<b>Chairs: To be announced</b>
20'	Sequencing the mesothelioma genome in 2015	Giorgio Scagliotti, IT
20'	The evolving role of thoracic surgeon	Walter Weder, CH
20'	Radiotherapist: controversial role in this disease	Umberto Ricardi, IT
20'	Systemic treatment: old drugs or new approaches?	Paul Baas, NL
10'	Questions and Answers	

<b>16:30-18:00</b> <b>Room A</b>	<b>Educational session</b> <b>Toxicity management of targeted agents</b>	<b>Chairs: To be announced</b>
20	Management of skin toxicity	Siegfried Segaert, BE
20	Uncommon (cardiac, hepatic, endocrine) toxicities of targeted agents and their management	Silvia Novello, IT
20	Interactions between targeted agents and concomitant meds including life style	Ron Mathijssen, NL
20	Interaction between radiotherapy and targeted agents: Toxicity issues	Francoise Mornex, FR
10'	Questions and Answers	

<b>18:30-19:30</b> <b>Room B</b>	<i>Industry Satellite Symposium 2</i>	
-------------------------------------	---------------------------------------	--

Thursday, 16 April 2015

<b>08:00-08:50</b> <b>Room A</b>	<b>Multidisciplinary Interactive Session (MIS)</b> <b>Oncogene-driven early stage NSCLC</b>	<b>Chairs &amp; Speakers</b>
15'	Should we test for EGFR and ALK in completely resected NSCLC?	Yi Long Wu, CN
15'	How should completely resected stage II-III with activating EGFR mutation be treated? ongoing studies	Mark Kris, US
20'	Discussion	

<b>08:00-08:50</b> <b>Room X</b> <b>(400)</b>	<b>Young Oncologists session I</b> <b>Molecularly-driven targeted agents for advanced NSCLC</b>	<b>Chairs: Speakers</b>
20'	Overcoming resistance to first-/second-generation EGFR-TKIs and ALK-inhibitors in oncogene-addicted advanced NSCLC	Raffaele Califano, UK and Mila Petrova, BG
20'	Novel therapies for advanced squamous cell carcinoma	Giannis Mountzios, GR
10'	Discussion	

<b>08:00-08:50</b> <b>Room V</b>	<b>Multidisciplinary Interactive Session (MIS)</b> <b>How do we provide the best psychological care for patients with thoracic malignancies?</b>	<b>Chairs &amp; Speakers</b>
15'	The holistic approach of the patient	Jean-Louis Pujol, FR
15'	The provision of early palliative care	Thierry Berghmans, BE
20'	Discussion	

Thursday, 16 April 2015, cont.

<b>09:00-10:30</b> <b>Room A</b>	<b>Educational session</b> <b>Management of neuro-endocrine tumours other than SCLC</b>	<b>Chairs: To be announced</b>
20'	Radionuclide techniques for staging and treatment	Eric Baudin, FR
20'	Local therapies	Bernward Passlick, DE
20'	Systemic therapy	Cesare Gridelli, IT
20'	Review of a current guideline	Martyn Caplin, UK
10'	Questions and Answers	

<b>09:15-10:15</b> <b>Room B</b>	<b>Controversy session</b> <b>Is immunotherapy a first-line treatment for NSCLC?</b>	<b>Chairs: To be announced</b>
10'	Introduction and first vote	
20'	Yes	Jean-Charles Soria, FR
20'	No	Michael Thomas, DE
10'	Second vote and conclusions	

<b>10:30-11:00</b>	<b>Coffee break</b>	
--------------------	---------------------	--

<b>11:00-12:30</b> <b>Room B</b>	<b>Specialty session</b> <b>How do we improve the outcome of stage III NSCLC?</b>	<b>Chairs: To be announced</b>
20'	Selection of patients for multimodality treatment decision	Wilfried Eberhardt, DE
20'	Optimal staging of mediastinal lymph nodes	Christophe Doods, BE
20'	Place of neo-adjuvant or adjuvant radiotherapy	Cecile Le Pechoux, FR
20'	Improving stage III outcome: any perspective?	Paul de Leyn, BE
10'	Questions and Answers / Panel Discussion	

<b>11:00-12:30</b> <b>Room A</b>	<b>Specialty session</b> <b>Personalised radiotherapy</b>	<b>Chairs: To be announced</b>
20'	The role of genetics in personalised radiotherapy	Catherine West, UK
20'	Organs at risk: How to individualise?	Dirk De Ruyscher, BE
20'	Radiomics for tumours: The future for personalised radiotherapy?	Olivier Gevaert, US
20'	How to individualise the combination of radiotherapy with drugs?	Daniel Zips, DE
10'	Questions and Answers / Panel Discussion	

<b>11:00-12:30</b> <b>Room C</b>	<b>Specialty session</b> <b>Contemporary resection techniques for stage I lung cancer</b>	<b>Chairs: To be announced</b>
20'	Minimally invasive open and hybrid techniques: Morbidity and long term results	Hisao Asamura, JP
20'	Conventional VATS lobectomy/segmentectomy: Morbidity and long term results	Hendrik Hansen, DK
20'	Uniportal VATS lobectomy/segmentectomy: Morbidity and long term results	Diego Gonzales-Rivas, ES
20'	Robotic lobectomy/segmentectomy: Morbidity and long term results	Robert Cerfolio, US
10'	Questions and Answers / Panel Discussion	

<b>11:00-12:30</b> <b>Room X</b>	<b>Specialty session</b> <b>Pathology in translation</b>	<b>Chairs: To be announced</b>
20'	Proliferation in lung cancer: Worth measuring?	Arne Warth, DE
20'	EQA for biomarker testing on the move	Erik Thunnissen, NL
20'	Diagnosing mesothelioma: An ongoing challenge	Sanja Dacic, US
20'	Liquid biopsies: CTCs and cell-free DNA for monitoring NSCLC	Stephen Finn, IE
10'	Questions and Answers / Panel Discussion	

Thursday, 16 April 2015, cont.

<b>11:00-12:30</b> <b>Room W</b>	<b>Specialty session</b> <b>The diagnostic challenge of small nodules</b>	<b>Chairs: To be announced</b>
20'	Optimal follow-up of incidental nodules	Walter De Wever, BE
20'	Possibilities and limitations of endoscopy	Vincent Ninane, BE
20'	Possibilities and limitations of transthoracic procedures	Stefan Diederich, DE
20'	Can biomarkers be of help in the diagnosis?	Gabriella Sozzi, IT
10'	Questions and Answers / Panel Discussion	

<b>12:30-13:10</b>	<b>Poster lunch</b>
--------------------	---------------------

<b>13:10-14:20</b> <b>Room C</b>	<i>Industry Satellite Symposium 3</i>
-------------------------------------	---------------------------------------

<b>14:30-16:00</b> <b>Room B</b>	<b>Proffered Papers 1</b>
-------------------------------------	---------------------------

<b>14:30-16:00</b> <b>Room A</b>	<b>Educational session</b> <b>Approaches to TKI resistance</b>	<b>Chairs: To be announced</b>
20'	Novel definition of TKI resistance: Clinical versus Molecular	Geoffrey Oxnard, US
20'	How to target T790M mutation?	Tony Mok, HK
20'	Management of EGFR-TKI resistance by local therapy, chemotherapy and antiangiogenesis	Martin Reck, DE
20'	Treatment options for ALK-TKI resistance	Dong Wan Kim, KR
10'	Questions and Answers	

<b>14:30-15:30</b> <b>Room V</b>	<b>Poster Discussion 1</b>
-------------------------------------	----------------------------

<b>16:00-16:30</b>	<b>Coffee break</b>
--------------------	---------------------

<b>16:30-18:00</b> <b>Room B</b>	<b>Educational session</b> <b>Locoregional treatment for oligometastatic lung cancer</b>	<b>Chairs: To be announced</b>
20'	Management of oligometastatic lung cancer and brain metastasis	Frederik Wnz, DE
20'	Surgery for oligometastatic lung cancer and liver or adrenal metastases	Paul Van Schil, BE
20'	Stereotactic ablative RT for oligometastatic lung cancer	Suresh Senan, NL
20'	Surgery for synchronous lung tumours	Giulia Veronesi, IT
10'	Questions and Answers	

<b>16:30-18:00</b> <b>Room A</b>	<b>Proffered Papers 2</b>
-------------------------------------	---------------------------

<b>18:20-19:20</b> <b>Room B</b>	<i>Industry Satellite Symposium 4</i>
-------------------------------------	---------------------------------------

<b>18:20-19:20</b> <b>Room C</b>	<i>Industry Satellite Symposium 5</i>
-------------------------------------	---------------------------------------

<b>19:30</b>	<b>Faculty Dinner</b>
--------------	-----------------------

Friday, 17 April 2015

<b>08:00-08:50</b> <b>Room A</b>	<b>Multidisciplinary Interactive Session (MIS)</b> <b>Heterogeneity in lung cancer: The elephant in the room?</b>	<b>Chairs &amp; Speakers</b>
15'	Impact of tumour heterogeneity on biomarker testing	Yasushi Yatabe, JP
15'	Genomic heterogeneity and clonal evolution in NSCLC	Charlie Swanton, UK
20'	Discussion	

<b>08:00-08:50</b> <b>Room X</b> <b>(400)</b>	<b>Young Oncologists 2</b> <b>Immunotherapy and translational research</b>	<b>Chairs: Speakers</b> Jesus Corral, ES and Matthew Krebs , UK
20'	Immune-checkpoint blockade for the treatment of advanced NSCLC	Jesus Corral, ES
20'	The promises and pitfalls of liquid biopsy for the molecular portrait and monitoring of treatment response in NSCLC	Matthew Krebs , UK
10'	Discussion	

<b>08:00-08:50</b> <b>Room W</b>	<b>Multidisciplinary Interactive Session (MIS)</b> <b>How to deal with multifocal adenocarcinoma?</b>	<b>Chairs &amp; Speakers</b>
15'	Surgical strategies and planning	Joseph Shrager, US
15'	Role of EGFR TKIs in non-metastatic multifocal adenocarcinoma	Marianne Nicolson, UK
20'	Discussion	

<b>09:00-10:30</b> <b>Room A</b>	<b>Educational session</b> <b>Functional evaluation early stage lung cancer</b>	<b>Chairs: To be announced</b>
20	Cardiopulmonary function testing: What makes sense?	Alessandro Brunelli, IT
20	Preoperative risk models: The choice between surgery and stereotactic RT	Eric Lim, UK
20	Predicted postoperative lung function: How low can we go?	David Waller, UK
20	What functional evaluation before chemoradiation?	José Belderbos, NL
10'	Questions and Answers	

<b>09:00-10:30</b> <b>Room C</b>	<b>Proffered papers 3</b>	
-------------------------------------	---------------------------	--

<b>09:15-10:15</b> <b>Room B</b>	<b>Controversy session</b> <b>Can adaptive design help to proceed in clinical trials in lung cancer?</b>	<b>Chairs: To be announced</b>
10'	Introduction and first vote	
20'	5 reasons pro	Benjamin Besse, FR
20'	5 reasons contra	Marc Buyse, BE
10'	Second vote and conclusions	

<b>10:30-11:00</b>	<b>Coffee break</b>	
--------------------	---------------------	--

<b>11:00-12:30</b> <b>Room B</b>	<b>Specialty session</b> <b>Are there new targets in advanced NSCLC?</b>	<b>Chairs: To be announced</b>
20'	Update of the French oncogenic platform	Fabrice Barlesi, FR
20'	Squamous carcinoma and its own targets	Roman Thomas, DE
20'	Lung cancer master protocols in the US	Fred Hirsch, US
20'	New targets relevant after the era of EGFR and ALK	Enriqueta Felip, ES
10'	Questions and Answers / Panel Discussion	

Friday, 17 April 2015, cont.

<b>11:00-12:30 Room A</b>	<b>Specialty session Locally-advanced NSCLC: Addressing the challenges of large-volume disease</b>	<b>Chairs: To be announced</b>
20'	Large volume LA-NSCLC disease: Definition and outcomes	Max Dahele, NL
20'	Is concurrent CT-RT superior in all large volume tumours?	Dirk De Ruyscher, BE
20'	Use of IMRT and proton therapy: Experimental or ready for prime-time?	Martin Stuschke, DE
20'	How to incorporate new agents and immunotherapy into the stage III treatment paradigm?	Rafal Dziadziusko, PL
10'	Questions and Answers / Panel Discussion	

<b>11:00-12:30 Room C</b>	<b>Specialty session Approach to sulcus superior tumours</b>	<b>Chairs: To be announced</b>
5'	Introduction	Dominique Grunenwald, FR
15'	Upfront surgery	Sacha Mussot, FR
15'	Transmanubrial approach	Hisao Asamura, JP
15'	Vertebral resection	Joachim Schirren, DE
15'	Role of systemic therapy	Egbert Smit, NL
15'	Role of radiotherapy	Paul Van Houtte, BE
10'	Discussion	

<b>11:00-12:30 Room X</b>	<b>Specialty session New WHO classification: Putting it into practice</b>	<b>Chairs: To be announced</b>
20'	Small biopsy and cytology diagnosis	Andrew Nicholson, UK
20'	Adenocarcinoma: What are the issues?	Bill Travis, US
20'	Tumours with squamous differentiation: What are the issues?	Ming Tsao, CA
20'	Undifferentiated tumours: What are the issues?	Keith Kerr, UK
10'	Questions and Answers / Panel Discussion	

<b>11:00-12:30 Room W</b>	<b>Specialty session Quality management in thoracic oncology</b>	<b>Chairs: To be announced</b>
20'	Guidelines in thoracic oncology: A European point of view	Marianne Paesmans, BE
20'	National and local care for patients with thoracic malignancies across Europe	Anna Rich, UK
20'	Quality of training in thoracic oncology: The HERMES programme	Fernando Gamarra, DE
20'	The European Initiative for Quality Management in Lung Cancer Care (EIQMLCC)	Torsten Blum, DE
10'	Questions and Answers / Panel Discussion	

<b>1230-13:10</b>	<b>Poster lunch</b>
-------------------	---------------------

<b>13:10-14:20 Room B</b>	<i>Industry Satellite Symposium 6</i>
-------------------------------	---------------------------------------

<b>13:10-14:20 Room C</b>	<i>Industry Satellite Symposium 7</i>
-------------------------------	---------------------------------------

## Friday, 17 April 2015, cont.

<b>14:30-16:00</b> <b>Room C</b>	<b>Multidisciplinary Tumour Board</b> <b>How do we approach oligoprogressive disease?</b>	<b>Chairs: To be announced</b>
30'	Controlled EGFR mutant disease and one rapidly growing lung nodule	Yi Long Wu, CN
30'	Crizotinib-controlled ALK positive disease and three brain metastases	Matthias Guckenberger, DE
30'	Cycle 28 pemetrexed maintenance therapy and one enlarging adrenal gland	Filippo de Marinis, IT

<b>14:30-15:30</b> <b>Room V</b>	<b>Poster Discussion 2</b>	
-------------------------------------	----------------------------	--

<b>16:00-16:30</b>	<b>Coffee break</b>	
--------------------	---------------------	--

<b>16:30-18:00</b> <b>Room B</b>	<b>ESMO-IASLC Best Abstracts</b>	<b>Chairs: To be announced</b>
	Session details to be defined	

<b>16:30-18:00</b> <b>Room A</b>	<b>Educational session</b> <b>Expanding the role of biomarkers</b>	<b>Chairs: To be announced</b>
20'	Biomarker testing beyond EGFR and ALK: Expanding the list of tests	Caicun Zhou, CN
20'	Biomarker testing on cytology samples	Lukas Bubendorf, CH
20'	Biomarker testing: Challenges in delivering the service	Fred Hirsch, US
20'	NGS techniques: Ready for 'prime time'?	Reinhard Büttner, DE
10'	Questions and Answers	

## Saturday, 18 April 2015

<b>08:00-08:50</b> <b>Room X</b>	<b>Multidisciplinary Interactive Session (MIS)</b> <b>Complex non T3 –T4 and non N2 resectable disease</b>	<b>Chairs &amp; Speakers</b>
15'	Pathological N1 disease: Extent of resection	David Waller, UK
15'	Invasion across the fissure: Extent of resection	Pascal Thomas, FR
20'	Discussion	

<b>08:00-08:50</b> <b>Room V</b>	<b>Multidisciplinary Interactive Session (MIS)</b> <b>Survivorship issues after stereotactic ablative RT for early-stage NSCLC</b>	<b>Chairs &amp; Speakers</b>
15'	Predicting survival following SABR in early-stage NSCLC	Umberto Ricardi, IT
15'	Treatment of disease detected post-SABR	Gaetano Rocco, IT
20'	Discussion	

<b>09:00-10:30</b> <b>Room B</b>	<b>Educational session</b> <b>Screening and early detection</b>	<b>Chairs: To be announced</b>
20'	Chemoprevention of lung cancer	Andrea De Censi, IT
20'	Molecular markers for early detection	Fabrizio Bianchi, IT
20'	Update on European lung cancer screening randomised and non-randomised studies	Nanda Horeweg, NL
20'	Update on Asian lung cancer screening randomised and non-randomised studies	Ryutaro Kakinuma, JP
10'	Questions and Answers	

Saturday, 18 April 2015, cont.

<b>09:00-10:30 Room C</b>	<b>Educational session Refining Radiation Therapy for SCLC</b>	<b>Chairs: To be announced</b>
20'	Radiobiology of SCLC and implications for treatment and research	Rebecca Bütof, DE
20'	Up-date Time-Dose-Fractionation-Schedule for thoracic radiochemotherapy in limited disease	Jose Belderbos, NL
20'	Indications, efficacy and toxicity of PCI in limited and extensive disease	Cecile Le Pechoux, FR
20'	Thoracic radiation therapy for extensive disease	Ben Slotman, NL
10'	Questions and Answers	

<b>10:30-11:00 Room B</b>	<b>ELCC Award Lecture</b>	<b>Chairs: To be announced</b>
	Session details to be defined	

<b>11:00-11:20</b>	Coffee break	
--------------------	--------------	--

<b>11:20-12:50 Room B</b>	<b>Educational session Smoking epidemiology and smoking cessation techniques</b>	<b>Chairs: To be announced</b>
20'	Molecular susceptibility for lung cancer and nicotine addiction	Gerard Zalcman, FR
20'	Smoking cessation in screening programmes	Paolo Boffetta, US
20'	Smoking cessation in young people	Anneke Bühler, DE
20'	Do electronic cigarettes impact on smoking cessation?	Elisabeth Quoix, FR
10'	Questions and Answers	

<b>11:20-12:50 Room C</b>	<b>Educational session The proper treatment algorithm for non-oncogene driven NSCLC</b>	<b>Chairs: To be announced</b>
20'	Optimal first line treatment	Kostas Syrigos, GR
20'	Treatment of the relapsed patient	Anne-Marie Dingemans, NL
20'	Chemotherapy for patients with brain metastases	Myung-Ju Ahn, KR
20'	Future direction: Pharamcogenomics or new chemotherapeutic agents?	Giorgio Scagliotti, IT
10'	Questions and Answers	

<b>12:50-13:00 Room B</b>	<b>Closing remarks</b>	<b>Chairs: Dominique Grunenwald, FR and Johan Vansteenkiste, BE</b>